1. Home
  2. HSDT vs SHPH Comparison

HSDT vs SHPH Comparison

Compare HSDT & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSDT
  • SHPH
  • Stock Information
  • Founded
  • HSDT N/A
  • SHPH 2012
  • Country
  • HSDT United States
  • SHPH United States
  • Employees
  • HSDT N/A
  • SHPH N/A
  • Industry
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • SHPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSDT Health Care
  • SHPH Health Care
  • Exchange
  • HSDT Nasdaq
  • SHPH Nasdaq
  • Market Cap
  • HSDT 2.5M
  • SHPH 2.3M
  • IPO Year
  • HSDT N/A
  • SHPH 2022
  • Fundamental
  • Price
  • HSDT $0.21
  • SHPH $3.48
  • Analyst Decision
  • HSDT Hold
  • SHPH
  • Analyst Count
  • HSDT 1
  • SHPH 0
  • Target Price
  • HSDT N/A
  • SHPH N/A
  • AVG Volume (30 Days)
  • HSDT 19.5M
  • SHPH 189.9K
  • Earning Date
  • HSDT 08-11-2025
  • SHPH 05-08-2025
  • Dividend Yield
  • HSDT N/A
  • SHPH N/A
  • EPS Growth
  • HSDT N/A
  • SHPH N/A
  • EPS
  • HSDT N/A
  • SHPH N/A
  • Revenue
  • HSDT $434,000.00
  • SHPH N/A
  • Revenue This Year
  • HSDT N/A
  • SHPH N/A
  • Revenue Next Year
  • HSDT $75.13
  • SHPH N/A
  • P/E Ratio
  • HSDT N/A
  • SHPH N/A
  • Revenue Growth
  • HSDT N/A
  • SHPH N/A
  • 52 Week Low
  • HSDT $0.20
  • SHPH $3.00
  • 52 Week High
  • HSDT $24.00
  • SHPH $107.40
  • Technical
  • Relative Strength Index (RSI)
  • HSDT 20.97
  • SHPH 37.82
  • Support Level
  • HSDT $0.30
  • SHPH $3.26
  • Resistance Level
  • HSDT $0.38
  • SHPH $4.10
  • Average True Range (ATR)
  • HSDT 0.13
  • SHPH 0.52
  • MACD
  • HSDT 0.04
  • SHPH 0.04
  • Stochastic Oscillator
  • HSDT 0.46
  • SHPH 15.08

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Share on Social Networks: